Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy With or Without Chemotherapy

NCT02874651 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT02874651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02874651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy With or Without Chemotherapy
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2016
Completion date
August 27, 2020
Enrollment
25 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal neoplasms